|
gptkbp:instanceOf
|
gptkb:drug
synthetic somatostatin analog
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
1995
|
|
gptkbp:ATCCode
|
H01CB03
|
|
gptkbp:brand
|
gptkb:Somatuline
|
|
gptkbp:CASNumber
|
108736-35-2
|
|
gptkbp:chemicalFormula
|
C54H69N11O10S2
|
|
gptkbp:contraindication
|
hypersensitivity to lanreotide
|
|
gptkbp:discoveredBy
|
gptkb:Ipsen
|
|
gptkbp:eliminationHalfLife
|
23-30 days
|
|
gptkbp:excretion
|
feces
|
|
gptkbp:form
|
solution for injection
pre-filled syringe
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lanreotide
|
|
gptkbp:KEGGID
|
D08141
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits glucagon secretion
inhibits insulin secretion
inhibits growth hormone secretion
|
|
gptkbp:MedlinePlusID
|
a605033
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
1096.3 g/mol
|
|
gptkbp:origin
|
gptkb:France
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
16129697
DB06791
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
injection site reactions
bradycardia
hyperglycemia
gallstones
gastrointestinal disturbances
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:UNII
|
7M87J0JV3Q
|
|
gptkbp:usedFor
|
gptkb:carcinoid_syndrome
acromegaly
neuroendocrine tumors
|
|
gptkbp:bfsParent
|
gptkb:somatostatin
gptkb:somatostatin_analogs
gptkb:Somatostatin_analogs
gptkb:Somatostatin
|
|
gptkbp:bfsLayer
|
7
|